Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system

References

• Italian Medicines Agency. [ cited 2016 Apr 29]. Available from http://www.agenziafarmaco.gov.it/it/content/registri-farmaci-sottoposti-monitoraggio
   Google Scholar
• International Society of Drugs Bulletins. ISDB Declaration on therapeutic advance in the use of medicines ISDB Meeting. Paris: 2001. [cited 2016 May 16]. Available from http://english.prescrire.org/Docu/Archive/docus/ISDBTherapAdvanceEN.pdf
   Google Scholar
• Branch SK, Agranat I. “New drug” designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity. J Med Chem. 2014;57(21):8729−8765.
   PubMed Web of Science ®Google Scholar
• Motola D, De Ponti F, Rossi P, et al. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol. 2005;59(4):475–478.
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency. [ cited 2016 Apr 29]. Available from http://www.agenziafarmaco.gov.it/it/content/l%E2%80%99innovazione-terapeutica-dei-nuovi-farmaci
   Google Scholar
• Directive 2010/84/EU of the European Parliament and of the Council. Official J Eur Union 2012; L 348:74–99. http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1477301106512&uri=CELEX:32010L0084. [cited 2016 Oct 20]
   Google Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VI – management and reporting of adverse reactions to medicinal products. [ cited 2016 May 16]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129135.pdf
   Google Scholar
• World Health Organization. Promoting rational use of medicines: core components. Geneva: WHO; 2002. cited 2016 May 30. Available from http://www.who.int/medicines/publications/policyperspectives/ppm05en.pdf
   Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. Bmj. 2004;329(7456):15–19.
   PubMed Web of Science ®Google Scholar
• Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. Jama. 1995;274(1):29–34.
   PubMed Web of Science ®Google Scholar
• McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331–1336.
   PubMed Web of Science ®Google Scholar
• Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions–a meta-analysis. PLoS One. 2012;7(3):e33236.
   PubMed Web of Science ®Google Scholar
• Medical Dictionary for Regulatory Activities (MedDRA). The MSSO - Maintenance and Support Services Organization. [ cited 2016 May 30]. Available from http://www.meddra.org/
   Google Scholar
• Palozzo AC. New drugs-how much are they worth? The Italian registries: a model to evaluate appropriateness and effectiveness. Eur J Hosp Pharm. 2012;19:398–403.
   Google Scholar
• Siviero PD. Managed-entry agreements as a way of enabling patient access to innovation. Ejop. 2012;6(3–4):30–31.
   Google Scholar
• Traversa G, Sagliocca L, Magrini N, et al. A perspective for the role of drug registries in the post-marketing surveillance. Recenti Prog Med. 2013;104:280–287.
   PubMedGoogle Scholar
• Klemp M, Frønsdal KB, Facey K. HTAi policy forum. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011;27(1):77–83.
   PubMed Web of Science ®Google Scholar
• Montilla S, Xoxi E, Russo P, et al. Monitoring registries at Italian medicines agency: fostering access, guaranteeing sustainability. Int J Technol Assess Health Care. 2015;31(4):210–213.
   PubMed Web of Science ®Google Scholar
• Montilla S, Marchesini G, Sammarco A, et al. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA anti-diabetics monitoring registry. Nutr Metab Cardiovasc Dis. 2014;24(12):1346–1353.
   PubMed Web of Science ®Google Scholar
• Weber J. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res. 1984;6:1–7.
   Google Scholar
• Hartnell NR, Wilson JP. Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24(6):743–749.
   PubMed Web of Science ®Google Scholar
• Hoffman KB, Dimbil M, Erdman CB, et al. The weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283–294.
   PubMed Web of Science ®Google Scholar
• Gidal B, Blum D. Abuse potential of antiepileptic drugs: a review using the vigibase pharmacovigilance database. Neurology. 2015;84(14):SupplementP1,233.
   Google Scholar
• Blieden M, Paramore LC, Shah D, et al. A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. Expert Rev Clin Pharmacol. 2014;7(3):341–348.
   PubMed Web of Science ®Google Scholar
• Lerose R, Musto P, Aieta M, et al. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. Eur J Clin Pharmacol. 2012;68(5):505–512.
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol. 2015;33(4):449–456.
   PubMed Web of Science ®Google Scholar
• Maratea D, Bettio M, Corti MG, et al. The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective. Ital J Pediatr. 2016;42(1):63.
   PubMed Web of Science ®Google Scholar
• Arocas Casañ V, Mateo Carmona J, García Molina O, et al. Off-label prescription of drugs at hospital. Farm Hosp. 2016;40(2):63–71.
   PubMedGoogle Scholar
• Formoso G, Marata AM, Magrini N, et al. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014;15(9):ED000090.
   Google Scholar
• Cohen D. Roche and Novartis colluded over wet AMD drugs, says Italian regulator. Bmj. 2014;9:348:g2006.
   Google Scholar
• Micromedex® 2.0 (electronic version) [database on the Internet]. Truven Health Analytics. Colorado, USA: Greenwood Village; [ cited 2016 May 3]. Available from http://www.micromedex.com/
   Google Scholar
• Sangrador Pelluz C, Maiques Llácer FJ, Soler Company E. Safety in the clinical practice of the triple therapy with telaprevir in chronic hepatitis C. Farm Hosp. 2013;37(6):489–493.
   PubMedGoogle Scholar
• Mancano MA. Ticagrelor-induced pneumonitis and subsequent pulmonary hemorrhage; drug rash with eosinophilia due to boceprevir; hepatitis C reactivation after starting infliximab; hydralazine-associated immune glomerulonephritis; fluoroquinolones and retinal detachment. Hosp Pharm. 2014;49(6):498–501.
   PubMedGoogle Scholar
• Shiraishi M, Umebayashi I, Matsuda H, et al. Postmarketing surveillance of telaprevir-based triple therapy for chronic hepatitis C in Japan. Hepatol Res. 2015;45(13):1267–1275.
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391–396.
   PubMed Web of Science ®Google Scholar
• Laroche ML, Charmes JP, Nouaille Y, et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol. 2007;63(2):177–186.
   PubMed Web of Science ®Google Scholar
• Van Der Heijden PG, Van Puijenbroek EP, Van Buuren S, et al. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med. 2002;21(14):2027–2044.
   PubMed Web of Science ®Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396.
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.
   PubMed Web of Science ®Google Scholar
• Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. BMC Clin Pharmacol. 2009;9:4.
   PubMedGoogle Scholar